We had an incredible turnout for the “A Licensing Deal for All Seasons” panel at #BIO2024, featuring our Chief Business Officer, Dr. Gavin Samuels. Panelists explored the current climate for deal-making in #biotech and #pharma and best practices, including the importance of transparency and trust in building mutually beneficial relationships in all seasons of the deal-making process.
CinRx Pharma
Biotechnology Research
Cincinnati, OH 1,895 followers
A hub and spoke biotech advancing a portfolio of high-impact medicines
About us
CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio.
- Website
-
http://www.cinrx.com
External link for CinRx Pharma
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cincinnati, OH
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Biotechnology and Drug Development
Locations
-
Primary
Get directions
5375 Medpace Way
Cincinnati, OH 45227, US
Employees at CinRx Pharma
Updates
-
CinRx CEO Jonathan Isaacsohn, MD, FACC, recently spoke with Kyle LaHucik at Endpoints News on CinRx's $73 million financing, the company's hub-and-spoke model, and what these funds mean for our portfolio of CinCos. Check out the article: https://bit.ly/3V6AoTx
-
CinRx Pharma successfully closed an additional $73 million financing, fueling our mission to address critical unmet medical needs and to expand our diverse portfolio of high-impact medicines. Learn more: https://lnkd.in/gQw4wVya
-
Next week, Gavin Samuels, CBO at CinRx, will join moderator Jonathan D. Grinstein, PhD of Inside Precision Medicine, and a panel of #lifesciences industry experts to discuss #dealmaking and partnerships in today’s #biotech landscape at #BIO2024 in #SanDiego. Details about the conference panel here: https://lnkd.in/eVTXgTt9 Uneek Mehra, 4D Molecular Therapeutics Kunal Patel, Synthekine Lesley Stolz, Johnson & Johnson Innovation Richard Wilson, Astellas Pharma Biotechnology Innovation Organization
-
-
#TeamCinRx and our GI portfolio companies, CinDome & CinPhloro, attended the Digestive Disease Week® (DDW) Annual Conference in Washington DC to connect with sites & investigators and learn about important research in the gastrointestinal motility field. #DDW2024
-
-
CinRx CEO Dr. Jonathan Isaacsohn, MD, FACC Isaacsohn was interviewed by Endpoints News’ Kyle LaHucik for an exclusive piece on CinDome’s recent $40M Series B financing extension, the unmet need in #gastroparesis and the CinRx hub-and-spoke portfolio approach. View the article here:
Gastroparesis biotech CinDome secures $40M for path to pivotal trial
https://endpts.com
-
CinRx and our portfolio companies recognize & thank the trailblazers who support our clinical trials including the patients, families, physicians, research sites and staff! THANK YOU! #ClinicalTrialsDay #CTD2024
-
-
CinDome Pharma, a CinRx portfolio company, secured a $40 million Series B financing extension from Perceptive Advisors and CinRx Pharma. This funding will support the ongoing development of deudomperidone (CIN-102) for the treatment of chronic #gastroparesis, marking a significant step towards potentially providing the first FDA-approved long-term therapy for adults with this condition. Find more details in our release: https://lnkd.in/ej5cskRv
-
Check out the new website for CinRx portfolio company, CinDome Pharma, which is focused solely on deudomperidone, a potentially safe, chronic therapy for #gastroparesis. Visit to learn more about our approach: https://cindome.com/
-
#ICYMI, CinRx CEO Jonathan Isaacsohn, MD, FACC's recent STAT First Opinion Piece discusses the #obesity landscape and the need for drug developers to prioritize preservation of lean muscle mass and energy expenditure in #weightloss treatments to achieve overall metabolic health. Read the full article here: https://lnkd.in/eyDYETsd